EdgePoint AI Computing Platform for Pharmaceutical and Healthcare
Revolutionary Cluster-Computer Platform for AI
EdgePoint AI was established to advance the company’s revolutionary cluster-computer platform for AI that processes machine learning models at a fraction of the power and budget of mainstream computing. We are implementing AI & vision powered Blockchain technology into our drug development process so that clinical development, clinical trials, and drug manufacturing can be done real time with full data integrity.
Telehealth AI Component for Remote Monitoring of Patient’s Respiratory Condition
AI Vision Grid Technology to Streamline Drug Manufacturing
Manufacturing Plant with Vision Camera Grid
Automatically track the real-time workflow of materials, personnel, equipment and products to achieve instant traceability and compliance.
Register events in a blockchain general ledger for immutability and auditability enhancing compliance.
Optimize traffic flow for efficiency in procedures and worker safety.
Potential to identify issues before product impact.
How It Works
Reduces number of camera, increases accuracy and slashes maintenance and installation costs with Sparcle™ software
CUBE Inference Hub
Fan-less hub of AI accelerator cluster connects wirelessly to cameras with Sparcle™ software
BRICK Data Aggregator
Low footprint embedded GPU silicon cluster computer replaces rack of servers for context data processing with Sparcle™ software
Mesh network cuts bandwidth needs, and reduces latency and deployment costs for real-time inference at the edge with Sparcle™ software
Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Mateon has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503).